Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer

Lung Cancer

Volumn 65, Issue 1, 2009, Pages 1-8

  Kakimi, Kazuhiro ^a   Nakajima, Jun ^a   Wada, Hiromi ^b,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c Wada Clinic   (Japan)

Author keywords

Adoptive transfer; Cancer vaccine; Cytotoxic T lymphocyte (CTL); Dendritic cell (DC); Immunotherapy

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; ANTINEOPLASTIC AGENT; BELAGENPUMATUCEL L; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD40 LIGAND; CETUXIMAB; DENDRITIC CELL VACCINE; ELOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR VACCINE; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HEAT SHOCK PROTEIN; INTERFERON; LUVCANIX; MATUZUMAB; MDX 214; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3 VACCINE; MUCIN 1; PANITUMUMAB; PERTUZUMAB; PROTEIN P53; RAS PROTEIN; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA2; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WT1 PROTEIN;

ANTIGEN EXPRESSION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; CELL THERAPY; CELL TRANSFER; CLINICAL TRIAL; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS;

EID: 67349233828     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.10.018     Document Type: Review

References (68)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Naruke T., Goya T., Tsuchiya R., and Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 96 (1988) 440-447
3. Bunn Jr. P.A., and Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist 13 (2008) 37-46
4. Ruttinger D., Hatz R.A., Jauch K.W., and Fox B.A. Current immunotherapeutic strategies in lung cancer. Surg Oncol Clin N Am 16 (2007) 901-918
5. Lucas S, Coulie PG. About human tumor antigens to be used in immunotherapy 2008;20:301-7.
6. Renkvist N., Castelli C., Robbins P.F., and Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50 (2001) 3-15
7. Gure A.O., Chua R., Williamson B., Gonen M., Ferreira C.A., Gnjatic S., et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 11 (2005) 8055-8062
8. Thompson J.A., Grunert F., and Zimmermann W. Carcinoembryonic antigen gene family-molecular-biology and clinical perspectives. J Clin Lab Anal 5 (1991) 344-366
9. Bruggen Pvd, Stroobant V, Pel AV, Eynde BVd. T-cell defined tumor antigens. In Cancer Immunity 2001 http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm.
10. Parmiani G., De Filippo A., Novellino L., and Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 178 (2007) 1975-1979
11. Adjei A.A. K-ras as a target for lung cancer therapy. J Thorac Oncol 3 (2008) S160-S163
12. Rosenberg S.A. Shedding light on immunotherapy for cancer. N Engl J Med 350 (2004) 1461-1463
13. Yano T., Sugio K., Yamazaki K., Kase S., Yamaguchi M., Ondo K., et al. Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer. Lung Cancer 26 (1999) 143-148
14. Kimura H., and Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 80 (1997) 42-49
15. Kimura H., and Yamaguchi Y. Adjuvant chemo-immunotherapy after curative resection of Stage II and IIIA primary lung cancer. Lung Cancer 14 (1996) 301-314
16. Ratto G.B., Cafferata M.A., Scolaro T., Bruzzi P., Alloisio A., Costa R., et al. Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer. J Immunother 23 (2000) 161-167
17. Ratto G.B., Zino P., Mirabelli S., Minuti P., Aquilina R., Fantino G., et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 78 (1996) 244-251
18. Chan B., Lee W., Hu C.X., Ng P., Li K.W., Lo G., et al. Adoptive cellular immunotherapy for non-small cell lung cancer: a pilot study. Cytotherapy 5 (2003) 46-54
19. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
20. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346-2357
21. Zhao Y., Zheng Z., Robbins P.F., Khong H.T., Rosenberg S.A., and Morgan R.A. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol 174 (2005) 4415-4423
22. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90 (1993) 3539-3543
23. Nemunaitis J., Dillman R.O., Schwarzenberger P.O., Senzer N., Cunningham C., Cutler J., et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 24 (2006) 4721-4730
24. Steinman R.M., and Banchereau J. Taking dendritic cells into medicine. Nature 449 (2007) 419-426
25. Anderson R.J., Schneider J., and Plasmid. DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 25 (2007) B24-B34
26. Van den Eynde B.J., and van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 9 (1997) 684-693
27. Atanackovic D., Altorki N.K., Stockert E., Williamson B., Jungbluth A.A., Ritter E., et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 172 (2004) 3289-3296
28. Vansteenkiste J., Zielinski M., Dahabre J., Linder A., Malinowski W., Jassem J., et al. Multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MADE-A3-positive, completely resected, non-small cell lung cancer (NSCLC). J Clin Oncol 24 (2006) 368s
29. Vansteenkiste J., Zielinski M., Linder A., Dahabre J., Esteban E., Malinowski W., et al. Adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebocontrolled Phase II study evaluating the MAGE-A3 cancer immunotherapeutic. Ejc Suppl 5 (2007) 361-1361
30. Atanackovic D., Altorki N.K., Cao Y., Ritter E., Ferrara C.A., Ritter G., et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 105 (2008) 1650-1655
31. Heymach J.V., Nilsson M., Blumenschein G., Papadimitrakopoulou V., and Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12 (2006) 4441s-4445s
32. Garcia B., Neninger E., de la Torre A., Leonard I., Martinez R., Viada C., et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 14 (2008) 840-846
33. Schlom J., Arlen P.M., and Gulley J.L. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 13 (2007) 3776-3782
34. Ho S.B., Niehans G.A., Lyftogt C., Yan P.S., Cherwitz D.L., Gum E.T., et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 53 (1993) 641-651
35. Kontani K., Taguchi O., Ozaki Y., Hanaoka J., Sawai S., Inoue S., et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med 12 (2003) 493-502
36. Rochlitz C., Figlin R., Squiban P., Salzberg M., Pless M., Herrmann R., et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 5 (2003) 690-699
37. Palmer M., Parker J., Modi S., Butts C., Smylie M., Meikle A., et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 3 (2001) 49-57
38. Butts C., Murray N., Maksymiuk A., Goss G., Marshall E., Soulieres D., et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23 (2005) 6674-6681
39. Sangha R., and Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 13 (2007) 4652s-4654s
40. Beebe M., Qin M., Moi M., Wu S., Heiati H., Walker L., et al. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy. Hum Vac 4 (2007) 210-218
41. Barve M., Bender J., Senzer N., Cunningham C., Greco F.A., McCune D., et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 26 (2008) 4418-4425
42. Marchetti A., Bertacca G., Buttitta F., Chella A., Quattrocolo G., Angeletti C.A., et al. Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clin Cancer Res 5 (1999) 2077-2081
43. Brunsvig P.F., Aamdal S., Gjertsen M.K., Kvalheim G., Markowski-Grimsrud C.J., Sve I., et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 55 (2006) 1553-1564
44. Bolonaki I., Kotsakis A., Papadimitraki E., Aggouraki D., Konsolakis G., Vagia A., et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 25 (2007) 2727-2734
45. Suda T., Tsunoda T., Daigo Y., Nakamura Y., and Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 98 (2007) 1803-1808
46. Hege K.M., Jooss K., and Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol 25 (2006) 321-352
47. Warren T.L., and Weiner G.J. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol 7 (2000) 168-173
48. Salgia R., Lynch T., Skarin A., Lucca J., Lynch C., Jung K., et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 21 (2003) 624-630
49. Nemunaitis J., Sterman D., Jablons D., Smith J.W., Fox B., Maples P., et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 96 (2004) 326-331
50. Nemunaitis J., Jahan T., Ross H., Sterman D., Richards D., Fox B., et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 13 (2006) 555-562
51. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., and Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64 (2004) 6337-6343
52. Berd D., Sato T., Maguire Jr. H.C., Kairys J., and Mastrangelo M.J. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 22 (2004) 403-415
53. Morris J.C., Vahanian N., Janik J.E., Moses L., Tennant L., Pittaluga S., et al. I study of an antitumor vaccination using {alpha}(13) galactosyltransferase expressing allogeneic tumor cells in patients (Pts) with refractory or recurrent non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 23 (2005) 2586
54. Raez L.E., Cassileth P.A., Schlesselman J.J., Padmanabhan S., Fisher E.Z., Baldie P.A., et al. Induction of CD8 T-cell-IFN-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Ther 10 (2003) 850-858
55. Raez L.E., Cassileth P.A., Schlesselman J.J., Sridhar K., Padmanabhan S., Fisher E.Z., et al. Allogeneic vaccination with a B7 1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 2800-2807
56. Dessureault S., Noyes D., Lee D., Dunn M., Janssen W., Cantor A., et al. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol 14 (2007) 869-884
57. Antonia S.J., Mirza N., Fricke I., Chiappori A., Thompson P., Williams N., et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12 (2006) 878-887
58. Ueda Y., Itoh T., Nukaya I., Kawashima I., Okugawa K., Yano Y., et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived HLA-A24-restricted CTL epitope: clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol 24 (2004) 909-917
59. Morse M.A., Clay T.M., Hobeika A.C., Osada T., Khan S., Chui S., et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 11 (2005) 3017-3024
60. Morse M.A., Hobeika A.C., Osada T., Serra D., Niedzwiecki D., Lyerly H.K., et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112 (2008) 610-618
61. Marshall J.L., Gulley J.L., Arlen P.M., Beetham P.K., Tsang K.Y., Slack R., et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 23 (2005) 720-731
62. Kaufman H.L., Lenz H.J., Marshall J., Singh D., Garett C., Cripps C., et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res 14 (2008) 4843-4849
63. Lake R.A., and Robinson B.W.S. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 5 (2005) 397-405
64. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2 (2002) 1-7
65. Appay V., Douek D.C., and Price D.A. CD8+ T cell efficacy in vaccination and disease. Nat Med 14 (2008) 623-628
66. Cote A.L., Usherwood E.J., and Turk M.J. Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle. Cancer Res 68 (2008) 1614-1617
67. Lizee G., Cantu M.A., and Hwu P. Less yin, more yang: confronting the barriers to cancer immunotherapy. Clin Cancer Res 13 (2007) 5250-5255
68. Choudhury A., Palma M., and Mellstedt H. The future of cancer vaccines for non-small-cell lung cancer: ongoing trials. Clin Lung Cancer 9 1 (2008) S37-44